Osteopontin is a prognostic biomarker in non-small cell lung cancer.

BMC Cancer 2013 Nov 11;13:540. Epub 2013 Nov 11.

Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Background: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating serum levels of OPN were measured and single nucleotide polymorphisms (SNP) in the -443 position of the OPN promoter were analyzed.

Methods: Associations between immunohistochemical expression of S100A4, OPN and ephrin-A1 and relapse free and overall survival were examined using univariate and multivariate analyses. Serum OPN was measured by ELISA, polymorphisms in the -443 position of the tumor OPN promoter were analyzed by PCR, and associations between OPN levels and promoter polymorphisms and clinicopathological parameters and patient outcome were investigated.

Results: High expression of OPN in NSCLC tumors was associated with poor patient outcome, and OPN was a strong, independent prognostic factor for both relapse free and overall survival. Serum OPN levels increased according to tumor pT classification and tumor size, and patients with OPN-expressing tumors had higher serum levels than patients with OPN-negative tumors. S100A4 was a negative prognostic factor in several subgroups of adenocarcinoma patients, but not in the overall patient cohort. There was no association between ephrin-A1 expression and patient outcome.

Conclusions: OPN is a promising prognostic biomarker in NSCLC, and should be further explored in the selection of patients for adjuvant treatment following surgical resection.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-13-540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830440PMC
November 2013
28 Reads

Publication Analysis

Top Keywords

opn
11
opn measured
8
serum levels
8
patient cohort
8
opn ephrin-a1
8
nsclc tumors
8
opn promoter
8
relapse free
8
prognostic factor
8
patient outcome
8
opn levels
8
serum opn
8
free survival
8
-443 position
8
lung cancer
8
cell lung
8
prognostic biomarker
8
non-small cell
8
patient
5
measured elisa
4

References

(Supplied by CrossRef)

A Jemal et al.
CA Cancer J Clin 2011

M Ishikawa et al.
Lung Cancer 2012

P Goldstraw et al.
Lancet 2011

AK Rud et al.
BMC Cancer 2012

K Boye et al.
Am J Pathol 2010

D Matsubara et al.
Cancer Sci 2005

K Kimura et al.
Int J Oncol 2000

M Tsuna et al.
Anticancer Res 2009

L De Petris et al.
Lung Cancer 2009

J Feng et al.
PLoS One 2012

J Wu et al.
Biomarkers 2012

Similar Publications